Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11098311
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11096927
Anti-flavivirus compounds and methods of use
granted -
US 11098150
Block copolymer and micelle compositions and methods of use thereof
granted -
US 11096929
Methods of treating developmental disorders with gaboxadol
granted -
US 11098052
4-azapodophylotoxins compounds
granted -
US 11097012
Biodegradable vectors for efficient RNA delivery
granted -
US 11098283
T cells modified to overexpress c-Myb
granted -
US 11096946
Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
granted -
US 11096965
Compositions and methods related to polycytotoxic T cells
granted -
US 11096956
Antisense oligomers and uses thereof
granted -
US 11098107
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
granted -
US 11096966
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
granted -
US 11097011
Peptide oligonucleotide conjugates
granted -
US 11098126
Anti-MET antibodies and uses thereof
granted -
US 11096997
Scaffolds for cell transplantation
granted -
US 11097017
Gadolinium-based contrast agents for sensitive detection of Zn2+with MRI
granted -
US 11097035
Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
granted -
US 11098109
Single-chain variable fragment anti-CD133 antibodies and uses thereof
granted -
US 11098054
Englerin derivatives for treatment of cancer
granted -
US 11098042
Inhibitors of influenza virus replication and uses thereof
granted -
US 11098025
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
granted -
US 11096996
Cancer vaccines and vaccination methods
granted -
US 11096964
Compositions and methods for immune cell modulation in adoptive immunotherapies
granted -
US 11096954
Bisphosphocin gel formulations and uses thereof
granted -
US 11097034
Compositions and methods of modulating endochondral ossification and bone formation
granted -
US 11098010
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
granted -
US 11096864
Adapter for a dispensing container in a planetary mixer
granted -
US 11098053
Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
granted -
US 11098084
Virus-like particles and methods of use
granted -
US 11098100
Therapeutic compounds and methods
granted -
US 11098101
Therapeutic compounds and methods
granted -
US 11098082
Antigenic peptides and uses thereof for diagnosing and treating autism
granted -
US 11098103
CD80 extracellular domain polypeptides and their use in cancer treatment
granted -
US 11096900
Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
granted -
US 11098112
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11098127
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
granted -
US 11098131
Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies
granted -
US 11099172
In vitro assays for inhibition of microglial activation
granted -
US 11096910
Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease
granted -
CA 3168610
MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS SOUFFRANT DE SCLEROSE EN PLAQUES
granted -
US 11103552
High concentration VEGF receptor fusion protein containing formulations
granted -
US 11103513
Natural combination hormone replacement formulations and therapies
granted -
US 11103472
Oral suspensions comprising a non-steroidal anti-inflammatory drug (NSAID)
granted -
US 11103462
Protein nanocapsules with detachable zwitterionic coating for protein delivery
granted -
US 11104712
Methods for modulating an immune response
granted -
US 11104957
Compositions and methods for treating cancers
granted -
US 11104706
Ang (1-7) derivative oligopeptides and methods for using and producing the same
granted -
US 11104708
Articles comprising a silk polypeptide for antigen delivery
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.